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Objective: To examine different aggrecanase generated fragments in synovial ﬂuid (SF) from patients with
acute and chronic knee injuries and from knee healthy subjects.
Methods: We prepared SF-D1 samples from acute (n¼ 35) and chronic (n¼ 35) knee injury patients and
knee healthy subjects (n¼ 10). Aggrecan fragments were analyzed in the SF-D1 samples by quantitative
(G1, ARGS, KEEE and G3 antibodies) and non-quantitative (GRGT and AGEG antibodies) Western blot.
Results: ARGS-SELE, ARGS-chondroitin sulfate (CS)1, GRGT-, GLGS- and AGEG-G3 fragments were the
main ARGS and G3 fragments in injured and reference samples. In the acute injury samples the
concentrations of these fragments were increased compared to the reference, and the level of the ARGS-
SELE remained elevated for at least 2 years after the joint injury.
Both SF ARGS fragments and aggrecanase generated G3 fragments had high sensitivity and speciﬁcity as
biomarkers in distinguishing injured from healthy knee joints, although the ARGS fragments had higher
area under the receiver operating characteristic curve (AUC) values for injuries (74e86%) than the G3
fragments (AUC values 63e68%).
Conclusion: Our results suggest that during the acute phase after knee injury there is an increased
aggrecanase activity against both the interglobular domain (IGD) and the CS2 cleavage sites of joint
cartilage aggrecan. This increase in SF aggrecanolytic fragments is present for several years after the
injury. SF ARGS fragments are better biomarkers than the aggrecanase generated G3-fragments in
distinguishing injured from healthy knee joints.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Articular cartilage degradation is a hallmark of arthritis and joint
injuries, involving an early loss of aggrecan fragments into synovial
ﬂuid (SF)1e3. Although both matrix metalloproteases (MMPs) and
calpains have shown to cleave aggrecan4, the major proteases
responsible for pathologic aggrecan degradation are the
aggrecanases4e6. Aggrecanase involvement in human arthritis and
knee injuries was ﬁrst shown by the cleavage in the aggrecan
interglobular domain (IGD) at the TEGE392Y393ARGSa site5,6, while: A. Struglics, Department of
nd, Sweden. Tel: 46-46-222-
glics).
based on full-length human
minal 1MTTL-(NCBI accession
s Research Society International. Paggrecanase cleavage in the chondroitin sulfate (CS) 2 region at
SELE1564Y1565GRGT, KEEE1733Y1734GLGS, TAQE1838Y1839AGEG and
ISQE1938Y1939LGQR sites was ﬁrst shown in bovine explant
cultures7,8 and later veriﬁed in bovine in vitro studies9,10. MMP
proteolysis in the IGD at the IPEN360Y361FFGV site was ﬁrst shown
in pig11 and human12 aggrecan, while MMP cleavage in the CS1
region was ﬁrst shown in bovine aggrecan13.
Several papers have reported on proteoglycan degradation
taking place following knee joint injuries1e3,14,15, but there are only
few papers providing details of the fragments generated during
aggrecan turnover16e18.
Quantitative analysis of aggrecan proteolytic fragments has
been conducted by enzyme-linked immunosorbent assay (ELI-
SA)15,19e26, electrochemiluminescence27 and by mass spectrom-
etry28. Western blot is considered a qualitative method, but is also
readily used for quantitative measurements29e31. We recently
developed a method for quantitative Western blot analysis of
aggrecan fragments18,32. In analysis of biological events and inublished by Elsevier Ltd. All rights reserved.
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conventional screening methods in differentiating fragments of
different sizes sharing the same epitope, providing a detailed
molecular pattern.
In the process of learning more about cartilage degradation
following joint injuries, we here combine a detailed fragment
analysis with the advantage of quantitative screening in Western
blot to examine aggrecan fragments in SFs from patients with acute
and chronic knee joint injuries and from knee healthy subjects. The
results provide a detailed mapping and quantitation of aggrecanase
generated fragments present in SF after human joint injuries.
Materials and methods
Antibodies and enzymes
Human recombinant ADAMTS-4 (a disintegrin and metal-
loproteinase with thrombospondin motifs, aggrecanase-1) and
aggrecan neo-speciﬁc anti-ARGSVILTVK monoclonal antibody
(characterized e Supplementary data Fig. S1; Refs. 17,22) were kind
gifts from M Pratta and Dr. S Kumar (GlaxoSmithKline). Polyclonal
aggrecan G1 (#PA1-1747) and G3 (#PA1-1745) domain antibodies
(recognizing the sequences: G1, CATEGQVRVNSIYQKVSL; G3,
CDGHPMQFENWRPNQPDN) were from Afﬁnity BioReagents
(Golden, CO., USA). The speciﬁcity of these antibodieswas conﬁrmed
byWestern blot blocking experiments (Supplementary data Fig. S1).
Aggrecan neo-speciﬁc anti-KEEE serum and anti-AGEG serumwere
kindgifts fromDr.MLark (Merck) and fromMPratta andDr. S Kumar
(GlaxoSmithKline), respectively. An aggrecan neo-speciﬁc anti-
GRGT serumwas made by Innovagen (Lund, Sweden). Speciﬁcity of
these antibodies was conﬁrmed by Western blot blocking using
immunogen peptides: CEVAPTTFKEEE, AGEGPSGILELC and GRGTI-
GISC (Supplementary data Fig. S1). All Western blot blocking
experiments were done using 10 mM immunogen-peptides incu-
batedwith antibody for 30 min at 22C prior addition tomembrane.
Peroxidase conjugated secondary antibodies were from Cell
Signaling Technology (goat anti-mouse IgG #7076), and from Kir-
kegaard & Perry Laboratories (KPL) (goat anti-rabbit IgG#074-1516).
Human SF samples
A SF osteoarthritis (OA) epool was made as described33. SF was
individually collected from 70 patients with knee injuries (35 acute
and 35 chronic) and from 10 knee healthy reference (REF) subjects
(Table I). Some of these SF samples have been used in previous
biomarkers studies3. All procedures were approved by the ethics
review committee of the Medical Faculty of Lund University.
Aggrecan SF-D1 isolation from SF
Mini SF-D1 preparations, collecting the lower half of the frac-
tions, were done in the presence of protease inhibitors from 35Table I
Characteristics of the subject groups
Study groups
sub-groups
n % male Age in years, mea
(range)
REF 10 90 34 (19e58)
AI 0e12 weeks
AI 0e2 weeks
AI 2e12 weeks
35
24
11
71
71
73
31 (20e61)
32 (20e61)
30 (20e60)
CI> 52 weeks
CI 52e104 weeks
CI > 104 weeks
35
12
23
77
83
74
37 (19e59)
36 (19e52)
37 (21e59)
Study groups: AI (anterior cruciate ligament tear, meniscus tear, collateral ligament tear, o
52e1,941 weeks between injury and sampling); REF (no history of joint injury and no kacute injury (AI), 35 chronic injury (CI) and 10 REF subjects as
described18. Sulfated glycosaminoglycan (sGAG; Alcian blue
precipitation) and protein (Pierce Micro BCA Assay) analysis of SF
and SF-D1 samples were conducted as described17. The average
sGAG yield in the SF-D1 samples was 77% [standard deviation
(SD)¼ 15, n¼ 79]. There was no correlation (rS¼ 0.062, P¼ 0.59;
n¼ 79) between the sGAG yield (range 45e124%) in SF-D1 and the
amount SF sGAG loaded (16e546 mg) on the CsCl gradients, sug-
gesting that the sGAG yields are not a result of differences of sGAG
loaded. The SF-D1 samples were deglycosylated by chondroitinase
ABC, keratanase and keratanase II and stored in lithium dodecyl
sulfate (LDS)esample buffer (Invitrogen) at 20C17.
Quantiﬁcation of aggrecan G1, ARGS, KEEE and G3 fragments by
Western blot
ARGS standard was made as described18, by ADAMTS4 digestion
of human OA cartilage A1D1 fraction, and the standard was
thereafter deglycosylated17. The digest was assessed for complete
conversion by Western blot using G1, ARGS and TEGE antibodies
(data not shown). The human OA cartilage A1D1 fraction, which the
ARGS standard was made from, contained no ARGS fragments
in vivo33 and only 39% of full length G1eG3monomers32. Therefore
we used an aggrecan molecular weight of 1.5106 g/mol (i.e., for
total protein sequence plus sGAG) which corresponds to
0.667 nmol ARGS fragments per mg aggrecan dry weight.
A bovine cartilage aggrecan A1D1 fraction, prepared from calf
(8e14 months old) metacarpophalangeal joints17, was used as G1
and G3 standards. This bovine A1D1 fraction contained 76.3%
(mean value; SD¼ 9%, n¼ 9 WB experiments) of full length
monomers (G1eG3 fragments), and by using full length molecular
weight of 2.5106 g/mol (¼0.4 nmol/mg), we assumed that the G1
and G3 standards contained 0.305 nmol (i.e., 0.763 0.4 nmol/mg)
G1eG3 fragments per mg aggrecan dry weight.
Since no KEEE standards were available, the SF D1 OA pool was
used as a control sample for the quantiﬁcation of KEEE fragments,
expressing the data as relative units of the control sample. Subject
SF D1 and the OA pool were run on same gels. Due to shortage of
subject SF-D1 samples, only one Western blot experiment (with all
available D1-samples) was run for detection of KEEE fragments.
Deglycosylated SF D1 samples and standards (i.e., ARGS, G1 and
G3 standards; three different concentrations per gel) were dena-
tured as described17, and together with Molecular weight markers
(10e250 kDa; Precision Plus Protein Standards BIO RAD) separated
by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) on 3e8% Tris-acetate midi-gels (26-wells, Invitrogen). The
proteins were electrophoretically transferred at 40 V for 70 min
onto polyvinylidene ﬂuoride (PVDF) membranes (BIO RAD
#1620230) using a Criterion Blotter (BIO RAD #170-4070) and
cooled 1NuPAGE transfer buffer (Invitrogen#NP0006) containing
10% methanol and 0.01% w/v SDS. Immuno-reactions were done as
described17, using anti-G1 (1.5 mg/ml), anti-ARGS (5.3 mg/ml), anti-n Time in weeks between injury and
sampling, mean (range)
OA scores, range
Na 1
2.2 (0e11.9)
0.7 (0e2)
5.4 (2.4e11.9)
1e5
1e4
1e5
278.1 (52.1e1,941)
67.3 (52.1e103.4)
388.4 (104.4e1,941)
1e7
1e5
1e7
steochondral fracture, 0e12 weeks from injury to sampling); CI (same injuries as AI,
nown joint pathology). OA score50. Na, not applicable.
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secondary peroxidase conjugated antibodies of goat anti-mouse IgG
(20 ng/ml) and goat anti-rabbit IgG (13.3 ng/ml). The immunobands
were visualized using ECL Plus Amersham Bioscience (ARGS and
KEEE) or SuperSignalWest Femto Pierce (G1 andG3) togetherwith
luminescence image analyzer (Fujiﬁlm LAS-1000). The positioning
and analysis of regions of interest of individual bands were done
using Fujiﬁlm software Image Gauge version 3.2.
The linearity of the ARGS, G1 and G3 standards (STD) was (sGAG
per lane): 0.03e4 mg (R2¼ 0.99), 0.1e3 mg sGAG (R2¼ 0.99) and
0.05e1.5 mg (R2¼ 0.95), respectively. Due to lack of space on gels,
only three concentrations of standards were run per gel (sGAG per
lane): ARGS-STD e 0.1, 0.5 and 1.5 mg; G1-STD e 0.5, 1 and 2.2 mg
and G3-STD e 0.2, 0.6 and 1 mg sGAG. SF-D1 samples which had
signals outside the range of the signal of the standards were rerun
on gels containing a broader signal range of the standards, so that
all the SF-D1 samples had signals whichwerewithin the linearity of
the corresponding standards.
Statistics
KruskaleWallis one way analysis of variance on ranks was used
to avoid mass signiﬁcance due to multiple group comparisons. If
signiﬁcances were found, then ManneWhitney rank sum tests for
analysis of unmatched pairs were run. For correlation analysis,
Spearman rank order correlation (rS) was used. P-values< 0.05
were considered signiﬁcant. Receiver operating characteristic
(ROC) curve analysis was done with Statistical Package for Social
Sciences (SPSS) software version 17.0.G1 G2IGD KS CS1
TEGE392|393ARGS
CS1G1
Region B (150-250)
KSG1
Region C (100-150)
CS1ARGS Region B (120-160)
G1
Region A (>250)
ARGS Region A (280-310)
ARGS Band-a1 (390)
CS1
Fig. 1. Aggrecan fragments detected byWestern blot in the SF-D1 fractions. A schematic il
an (between G1 and G2) IGD, a KS enriched region and two CS (CS1 and CS2) regions; and
fragments: region-A (>250 kDa), -B (150e250 kDa) and -C (100e150 kDa). ARGS fragment
fragments: band-b (CS1-KEEE, 124 kDa) and -c (GRGT-KEEE, 50 kDa). G3 fragments with agg
(AGEG-G3, 137 kDa) and -d (LGQR-G3, 103 kDa). Aggrecanase cleavage sites are shown aboResults
Quantitative Western blot screening of ARGS and G3 fragments
The aggrecan fragments detected by Western blot in the
subjects’ SF-D1 fractions and discussed here are illustrated in Fig. 1.
For each of the ARGS and G3 antibodies each subject’s SF-D1
sample, together with standards, were analyzed three times by
SDS-PAGE and immuno blotting (i.e., n¼ 3 different Western blot
experiments). For each subject; the mean, median, SD and coefﬁ-
cient of variation (CV) of aggrecan fragment concentrations were
calculated. All data were corrected for the sGAG yields in the SF-D1
preparations, assuming that identical types of fragments were
present in the recovered vs unrecovered material.
The within-patient CVs (based on the triplicates) for the total
ARGS signal varied between the subjects, with an overall average
(n¼ 77 subjects) of 25%. The average CV for ARGS regions A and B
was 40% and 29%, respectively (Supplementary data Table SI).
Similar analysis of the G3 aggrecan fragments showed average CVs
between 41 and 64% (Supplementary data Table SI). Due to the high
CV values, the median value for each patient was used for the
calculation of group medians used in the comparisons between
diagnostic groups.
SF aggrecanase generated ARGS fragments are increased following
injury
Aggrecan fragments were puriﬁed by CsCl density centrifuga-
tion from SF of individuals, collecting the D1-fractions from theG3CS2
SELE1564|1565GRGT
KEEE1733|1734GLGS ISQE1938|1939LGQR
TAQE1838|1839AGEG
G3GRGT Band-a (214)
G3GLGS Band-b (171)
G3AGEG Band-c (137)
G3
(103)LGQR
Band-d
CS2 G3
CS1 CS2
CS2
GRGT KEEE
Band-c
(50)
Band-b (124) KEEE
lustration of full length aggrecan: composed of three globular domains (G1, G2 and G3),
fragments of aggrecan detected by Western blot in the SF-D1 fractions of subjects. G1
s: region-A (280e310 kDa) and -B (120e160 kDa), and ARGS band-a1 (390 kDa). KEEE
recanase generated N-terminals: band-a (GRGT-G3, 214 kDa), -b (GLGS-G3, 171 kDa), -c
ve.
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Fig. 2. Concentration of aggrecan ARGS-fragments in the study groups. Total ARGS, ARGS region-A (280e310 kDa) and region-B (120e160 kDa) were quantiﬁed in SF-D1 samples
by Western blot using ADAMTS4 digested human cartilage-A1D1 fraction as ARGS-standards. The boxes deﬁne the twenty-ﬁfth and seventy-ﬁfth percentile with a line at the
median, error bars deﬁne the tenth and ninetieth percentile and circles represent individual outliers. *Indicates signiﬁcance (P< 0.05) between injury and reference groups. Actual
P-values are shown in Table II. Diagnostic groups are as in Table I.
A. Struglics et al. / Osteoarthritis and Cartilage 19 (2011) 1047e10571050lower half of the gradient. The Western blot showed that the D1
samples contained two ARGS fragment regions termed A
(280e310 kDa) and B (120e160 kDa) (Supplementary data Fig. S2).
The A-region contained 393ARGS-CS1/CS2 fragments e mainly the
aggrecanase generated 393ARGS-SELE1564 fragment (310 kDa), but
some of the injury SF-D1 samples also contained a 280 393ARGS-
CS1 fragment with a C-terminal previously identiﬁed as calpain
generated EDLS1472 (Refs.18,32). The B-region contained 393ARGS-
CS1 fragments with multiple C-terminals previously estimated as
MMP generated GV(G/E)D952e1409 (Refs.17,18). In addition, approxi-
mately 50% of the injury patients (acute and chronic) and 10% of the
knee healthy controls (reference) had an additional 390 kDa ARGS-Table II
Aggrecan ARGS fragments in human SF samples. Concentration (in pmol/ml SF) of total AR
antibody and human ARGS standards. Concentrations, expressed as median (minemax r
against the reference group. P-values, signiﬁcant analysis (ManneWhitney) of injury vs
Diagnostic groups n Total ARGS Norm P-values ARGS r
REF 10 1.3 (0.5e12.0) 1 e 0.15 (0
AI 0e2 weeks 24 44.7 (7.6e193.0) 33.5 <0.001 14.6 (0
AI 2e12 weeks 11 6.6 (2.1e53.4) 4.9 0.001 2.1 (0
CI 52e104 weeks 12 2.7 (0.8e18.6) 2.0 0.106 0.63 (0
CI> 104 weeks 20 1.3 (0.2e239.0) 1.0 0.524 0.24 (0
Diagnostic groups n ARGS re
REF 10 0.30 (0.
AI 0e12 weeks 35 0.64 (0e
CI> 52 weeks 32 0.62 (0.CS2 fragment (band-a1) with an estimated (using a calculation
model)34 C-terminal of TAQE generated by an aggrecanase cut at
the TAQE1838Y1839AGEG site (Supplementary data Fig. S2).
In the AI groups the total ARGS concentration was 33 times (AI,
0e2 weeks) and ﬁve times (AI, 2e12 weeks) higher than in the REF
group, while in the CI groups (52e104 weeks and >104 weeks) the
total ARGS signal did not differ from the reference level [Fig. 2(a),
Table II]. In the injury groups, ARGS fragments constituted 5e28% of
total aggrecan, and were signiﬁcantly increased for many years
compared to reference levels (Table III). Both ARGS region-A and -B
concentrations were increased in the AI groups (99 times for ARGS
region-A in the 0e2 weeks group). While the ARGS region-A levelGS, ARGS region-A and -B wasmeasured in SF-D1 samples usingWestern blot, ARGS
ange) values in diagnostic groups. Median values of ARGS were normalized (Norm)
reference group. Diagnostic groups were according to Table I
egion-A Norm P-values ARGS region-B Norm P-values
.1e1.6) 1 e 0.75 (0.2e9.5) 1 e
.4e106.3) 98.6 <0.001 23.0 (3.0e56.9) 30.9 <0.001
.2e20.2) 13.9 <0.001 3.4 (0.5e29.7) 4.5 0.004
.2e5.1) 4.3 0.004 0.78 (0.3e7.3) 1.0 0.489
e81.4) 1.6 0.153 0.59 (0.1e98.5) 0.8 0.843
gion A/B Norm P-values
1e0.74) 1 e
2.13) 2.1 0.012
1e3.53) 2.0 0.010
Table III
Concentration of sGAG, aggrecan and ARGS fragments in human SF samples. Concentration of total aggrecan (pmol/ml SF) was calculated from the Alcian Blue sGAG
concentration (mg GAG/ml SF) assuming that 75% of total aggrecanmolecular weight (Mw) comes from GAG and assuming a aggrecan total Mw of 1,500,000 g/mol. Proportion
ARGS (%) is the estimated proportion of ARGS fragments out of total amount aggrecan. Concentrations, expressed as median (minemax range) values in diagnostic groups.
Median values of sGAG and proportion ARGS were normalized (Norm) against the reference group. P-values, signiﬁcant analysis (ManneWhitney) of injury vs reference group.
Diagnostic groups were according to Table I. Total ARGS (pmol/ml SF) is from Table II
Diagnostic groups n sGAG Norm P-values Aggrecan Total ARGS Proportion ARGS Norm P-values
REF 10 59.9 (17.8e118.3) 1 e 53.2 (18.8e105.2) 1.3 (0.5e12.0) 2.5 (1.2e20.0) 1 e
AI 0e2 weeks 24 167.8 (29.0e504.3) 2.8 <0.001 149.1 (25.8e448.3) 44.7 (7.6e193.0) 27.5 (6.1e70.2) 11.0 <0.001
AI 2e12 weeks 11 86.6 (45.1e237.5) 1.5 0.038 77.0 (40.1e211.2) 6.6 (2.1e53.4) 11.9 (2.9e31.1) 4.8 0.002
CI 52e104 weeks 12 50.1 (23.1e124.9) 0.8 0.448 44.5 (20.5e111.0) 2.7 (0.8e18.6) 5.6 (2.6e41.0) 2.2 0.011
CI> 104 weeks 20 45.8 (14.7e476.3) 0.8 0.613 40.7 (13.1e423.4) 1.3 (0.2e239.0) 4.7 (1.1e56.5) 1.9 0.045
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concentration had returned to the reference level in the chronic
groups [Fig. 2(b and c), Table II]. The ARGS region A/B ratio was
higher in both AI and CI groups when compared to the reference
[Fig. 2(d), Table II], and the level of the 390 kDa ARGS-CS2 fragment
(band-a1) was increased in the CI group compared to the reference
(P¼ 0.007, data not shown).
These results conﬁrm previous observations of a marked release
of aggrecanase-generated ARGS fragments in the acute phase
following injury, and that ARGS fragments represent a large propor-
tion of total aggrecan in these SF samples. Further, although the
overall SF ARGS concentration did not signiﬁcantly differ from
reference level 2 years after injury, the differences in ARGS region
fragment A and B proportions between injury and control groups
suggest a persistent change in aggrecan turnover many years after
the joint injury.Fig. 3. Aggrecanase generated CS2-G3 fragments detected in SF-D1 fractions. Four
major aggrecanase generatedCS2-G3 fragmentsweredetected in the SF-D1 fractions from
the subjects (see Supplementary Fig. S3): to identify the N-terminal of these fragments,
the SF-D1 OA pool (SF), cartilage A1D1-aggrecan (C) and ADAMTS-4 in vitro digested
cartilage A1D1-aggrecan (C1-C3) was separated by SDS-PAGE (3e8%, 15 wells gel),
transferred to PVDF-membrane and probed with anti-GRGT (sera, 1:1,000), -AGEG (sera,
1:1,000) and -G3 (2 mg/ml) antibodies as previously33. The data conﬁrm the presence of
aggrecanase generated GRGT-G3 (214 kDa) and AGEG-G3 (137 kDa) fragments in the SF-
D1 samples, and theMwmigration pattern of G3 fragments also suggests the presence of
GLGS-G3 (171 kDa) and LGQR-G3 (103 kDa) fragments. 0.5e4 mg sGAG of samples was
loadedper lane. C, cartilageA1D1; C1, cartilageA1D1digested for 15 minwithADAMTS-4;
C2, cartilage A1D1digested for 24 hwith ADAMTS-4; C3, cartilage A1D1digested for 0.5 h
with ADAMTS-4. Cartilage A1D1was prepared froma cartilage OA-pool and theADAMTS-
4 in vitro digest was as previously17. D¼ dimer of the AGEG-G3 fragment. Band marked
byþ is considered to be a false-positive immunoband since it could not be blocked by the
corresponding immunogen peptide.SF aggrecanase generated CS2-G3 fragments are increased following
injury
The G3 Western blot showed that the SF D1-fractions prepared
from the subjects contained G1eG3 monomers (>400 kDa), and
aggrecanase generated 214 kDa 1565GRGT-G3, 171 kDa CS2-G3,
137 kDa 1839AGEG-G3 and 103 kDa CS2-G3 fragments
(Supplementary data Fig. S3). The GRGT and AGEG N-terminals of
these CS2-G3 fragments were veriﬁed by neo-epitope antibodies,
while the 103 and 171 kDa CS2-G3 fragments were estimated by
calculation34 as 1939LGQR-G3 and 1734GLGS-G3, respectively (Fig. 3).
The SF concentrations of full length G1eG3 monomers did not
differ signiﬁcantly between the injury and reference groups
[Fig. 4(a), Table IV]. The LGQR-G3 fragment was only found in some
of the injured and none of the uninjured samples, and was there-
fore not analyzed further (data not shown). On the other hand the
GRGT-, GLGS- and AGEG-G3 were the dominant G3 fragments in
both injured (mean¼ 79% of total G3-signal, SD¼ 21%, n¼ 68) and
reference (mean¼ 70% of total G3-signal, SD¼ 26%, n¼ 9) samples,
but the SF concentrations of the aggrecanase generated GRGT-,
GLGS- and AGEG-G3 fragments were increased in the AI samples
compared to the reference, where the AGEG-G3 fragment increased
most (12 times, in the 0e2 weeks AI group) [Fig. 4(bed), Table IV].
At 2 years after injury the SF concentrations of these G3-fragments
did not differ from the reference levels [Fig. 4(bed), Table IV].
The relative amounts of aggrecanase generated G3 fragments in
the SF reference ﬂuids were [GLGS-G3]> [GRGT-G3]> [AGEG-G3],
although in the 0e2 weeks AI group the AGEG-G3 was the domi-
nant G3 fragment (Table IV). The relative proportion of these G3
fragments differed between the AI group (0e12 weeks) and the
reference (lower proportions of GRGS- and GLGS-G3 fragments and
higher proportion of AGEG-G3), but the proportions were
normalized in the CI group (>52 weeks) [Fig. 4(e)].
These results suggest that aggrecanase activity against sites in
the CS2 region is increased directly after injury, which results inhigh SF concentrations of GRGT-, GLGS- and AGEG-G3 fragments.
Further, the SF concentrations of these G3-fragments are reduced to
reference levels at 2 years from injury.
ARGS and G3 fragments as biomarkers for joint injuries
There were no differences in the SF median total ARGS
concentration (measure of the aggrecanase cut in the IGD) between
men and women comparing all (P¼ 0.576) or only injured subjects
(P¼ 0.383). Similarly, therewere no differences between genders in
the SF median GRGT-, GLGS- and AGEG-G3 fragment concentra-
tions (measure of aggrecanase cuts in the CS2 region) of all
(P¼ 0.138,¼0.155 and¼0.208 respectively) or only injured subjects
(P¼ 0.102, ¼0.115 and ¼0.150 respectively).
The sensitivity and speciﬁcity was high for aggrecanase gener-
ated SF ARGS (ARGS region-A, -B and total ARGS) and G3 (GRGT-G3,
GLGS-G3 and AGEG-G3) fragments as markers for joint injuries (i.e.,
AI alone or AIþ CI) (Table V). There were no major differences
a c
b d
e
Fig. 4. Concentration of aggrecan G3-fragments in the study groups. G3 fragments were quantiﬁed in SF-D1 samples by Western blot using bovine cartilage-A1D1 fraction as
G3-standards. SF concentrations of G1eG3 (a), GRGT-G3 (b), GLGS-G3 (c), AGEG-G3 (d) are shown. The proportion of G3 fragments was calculated (from mol concentrations) as the
ratio of a G3 fragment over the sum of GRGT-G3 (band-a), GLGS-G3 (band-b) and AGEG-G3 (band-c) fragments (e). The boxes deﬁne the twenty-ﬁfth and seventy-ﬁfth percentile
with a line at the median, error bars deﬁne the tenth and ninetieth percentile and circles represent individual outliers. *Indicates signiﬁcance (P< 0.05) between injury and
reference groups. Actual P-values for (a) e (d) are shown in Table IV. Diagnostic groups are as in Table I.
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although all of them had higher area under the ROC curve (AUC)
values for AI (94e98%) and for AIs plus CIs (74e86%) compared to
corresponding AUC values (AI, 72e83%; AIþ CI, 63e68%) of the G3
fragments (Table V).
These results suggest that of the high Mw aggrecan fragments
found in SF-D1 samples, ARGS fragments are better biomarkers in
distinguishing injured from healthy knee joints compared to
aggrecanase generated G3 fragments (i.e., GRGT-G3, GLGS-G3 and
AGEG-G3), and that gender has no inﬂuence in these comparisons.Differences in the high Mw SF aggrecan fragment pattern between
injured and knee healthy subjects visualized by Western blot
The 80 SF-D1 samples were screened for high Mw (i.e., sGAG
containing) aggrecan fragments by Western blot with antibodies
recognizing G1 and G3 domains, and with antibodies against
aggrecanase generated neoepitope ARGS and KEEE.
As shown above the aggrecanase generated ARGS region-A and
-B, and band-a1, were all increased compared to the reference
following injury [Fig. 5(a)]. Similarly, the GRGT-G3, GLGS-G3 and
Table IV
Aggrecan G3 fragments in human SF samples. Concentration (in pmol/ml SF) of G1eG3, GRGT-G3, GLGS-G3 and AGEG-G3 fragments was measured in SF-D1 samples using
Western blot, G3 antibody and bovine G3 standards. Concentrations, expressed as median (minemax range) values in diagnostic groups. Median values of G3 fragments were
normalized (Norm) against the reference group. P-values, signiﬁcant analysis (ManneWhitney) of injury vs reference group. For the GRGT-G3 fragment; the KruskaleWallis
test of random sampling variability was not signiﬁcant (the P-values was therefore not determined, Nd), although the KruskaleWallis test was signiﬁcant for time periods AI
(0e12 weeks) and CI (>52 weeks) where the AI vs reference differed signiﬁcantly (P¼ 0.048). Diagnostic groups were according to Table I
Diagnostic groups n G1eG3 Norm P-values
REF 9 1.4 (0e3.3) 1 e
AI 0e2 weeks 24 0.36 (0e4.4) 0.3 0.129
AI 2e12 weeks 11 1.2 (0e4.8) 0.9 0.939
CI 52e104 weeks 12 1.9 (0.3e9.7) 1.4 0.337
CI> 104 weeks 21 1.1 (0e8.5) 0.8 0.928
Diagnostic groups n GRGT-G3 Norm P-values GLGS-G3 Norm P-values AGEG-G3 Norm P-values
REF 9 0.80 (0.5e6.0) 1 e 1.0 (0.5e8.8) 1 e 0.46 (0.2e4.8) 1 e
AI 0e2 weeks 24 2.0 (0.3e8.6) 2.6 Nd 2.0 (0.5e17.4) 2.0 0.022 5.5 (0.3e19.9) 11.9 0.003
AI 2e12 weeks 11 1.9 (0.3e9.1) 2.4 Nd 3.9 (0.6e20.0) 3.8 0.129 2.5 (0.3e35.4) 5.5 0.033
CI 52e104 weeks 12 1.3 (0.1e1.9) 1.7 Nd 1.5 (0.3e4.5) 1.5 0.972 0.77 (0.1e4.2) 1.7 0.696
CI> 104 weeks 21 0.86 (0.2e4.7) 1.1 Nd 1.2 (0.2e17.3) 1.1 0.856 0.68 (0.1e43.4 1.5 0.928
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124 kDa CS1-KEEE fragment (band-b) with an estimated MMP
generated N-terminal of ISGL, and a 50 kDa aggrecanase generated
GRGT-KEEE fragment (band-c) were also signiﬁcantly increased
during injury [Fig. 5(a), Supplementary data Fig. S4(a)]. G1 frag-
ments in region-A (Mw> 250 kDa; G1eG3 monomers and G1-CS2
with aggrecanase generated KEEE/SELE) and region-B
(Mw¼ 150e250 kDa; G1-CS1 with an estimated MMP generated
C-terminal of GVED) were the dominant G1-fragments in the
reference group (data not shown). The concentrations of G1 region-
B fragments were signiﬁcantly reduced in the injury groups, while
G1 region-C fragments (Mw¼ 100e150 kDa; G1-keratan sulfate
(KS) with unknown C-terminal) were signiﬁcantly increased during
AI, all compared to the reference group [Fig. 5(a), Supplementary
data Fig. S4(b)].
These results suggest that there is a high Mw (>100 kDa)
aggrecanase generated SF aggrecan injury pattern which is signif-
icantly different from the turnover pattern of the REF group
[illustrated in Fig. 5(b)]. This difference in pattern is due to elevated
aggrecanase proteolysis against both the IGD and CS2 sites of
aggrecan in injured joints.
Discussion
We have previously presented a quantitative Western blot
method for aggrecan fragments where we analyzed a few SF-D1
samples from ﬁve diagnostic groups18. In the present paper weTable V
Sensitivity and speciﬁcity of aggrecanase generated SF ARGS and G3 fragments in
distinguishing between injured and healthy knee cartilage. Concentrations (in pmol/
ml SF) of ARGS region-A, ARGS region-B, total ARGS, GRGT-G3, GLGS-G3 and AGEG-
G3 fragmentsweremeasured in SF-D1 samples usingWestern blot and human ARGS
or bovine G3 standards. The data (in %): comparison between AI (0e12 weeks) and
reference (healthy), and between AI (0e12 weeks) plus CI (>52 weeks) and refer-
ence. Diagnostic groups were according to Table I
Biomarkers AI AIs and CIs
AUC Sensitivity Speciﬁcity AUC Sensitivity Speciﬁcity
ARGS region A 98 97 90 86 74 90
ARGS region B 94 94 90 74 64 90
ARGS total 96 94 90 80 69 90
GRGT-G3 72 71 78 63 60 78
GLGS-G3 75 83 67 63 69 67
AGEG-G3 83 69 89 68 72 67
Sensitivity¼ the proportion of positives (diseased) correctly identiﬁed by the test.
Speciﬁcity¼ the proportion of negatives (healthy) correctly identiﬁed by the test.have considerably extended the patient numbers, focusing on AIs
and CIs in comparison with knee healthy subjects, and in a detailed
analysis provide quantitative and qualitative information on addi-
tional aggrecan fragments.
CsCl puriﬁcation of SF aggrecan together with Western blot
analysis allowed quantitative detection of high Mw (>100 kDa)
aggrecanase generated fragments from seventy knee injured and
ten knee healthy subjects. These measurements showed that
directly after injury (within 2 weeks) there was an increased
aggrecanase cleavage in the aggrecan IGD, generating ARGS-SELE
and ARGS-CS1 fragments. Similarly increased aggrecanase cuts
were seen against the aggrecan CS2 sites generating GRGT-G3,
GLGS-G3 and AGEG-G3 fragments. The levels of the aggrecanase
generated G3 fragments were normalized 2 years after injury,
although there was still a difference in the ARGS-SELE/ARGS-CS1
ratio between injury and reference. Further, the SF patterns of G1
and KEEE fragments were also markedly changed after injury.
Together these data show that there is a change in the aggrecan
turnover lasting many years after knee injury.
Several of the aggrecan fragments found in these SF-D1 samples
were generated by aggrecanase digestion in combination with cuts
by MMPs (e.g., ARGS-GVED, ISGL-KEEE) or calpains (ARGS-EDLS).
Also, MMP generated FFGV fragments have been detected in SF-D1
samples17, but calpain generated PGVA and GDLS fragments32 were
not found in these SF-D1 samples (data not shown). Even though
some of the MMP and calpain cuts of aggrecan might be involved in
normal turnover, it is also possible that these enzymes have an
active role in the degradation processes following joint injuries.
Knee injuries are accompanied by increased SF levels of pro-
inﬂammatory cytokines35, and increased levels of ARGS frag-
ments have been observed in explant studies when stimulating
cartilage with cytokines22,36e38. Mechanically injured bovine
cartilage discs have an increased mRNA expression of cartilage
matrix degrading enzymes39 which result in proteoglycan and
collagen degradation in these tissues40,41. Increased SF levels of
proteoglycans and/or aggrecan2,3 and the aggrecan neoepitope
ARGS15,18 directly after knee injury (i.e., acute phase 0e12 weeks)
are well established. Our results (Figs. 2 and 3, Table II) support
these ﬁndings, which are now extended by our Western blot data
showing that concentrations of both ARGS-SELE and ARGS-CS1
fragments are increased, and that the ratio of these fragments is
constantly higher in the injury group compared to reference for
many years after injury.
SF-ARGS ELISA measurements can distinguish diseased joints
(i.e., arthritis and joint injury) from reference joints with
high sensitivity and speciﬁcity15, and a similar differentiation in
Fig. 5. The pattern of high Mw SF aggrecan fragments from knee injury patients and reference subjects. The high Mw (i.e., sGAG containing) aggrecan fragment pattern in
SF-D1 fractions was analyzed, by Western blot, from knee injured patients (AI 0e12 weeks and CI> 52 weeks) and REF. (a) Characteristic high Mw G1, ARGS, KEEE and G3 aggrecan
fragment pattern from speciﬁc subjects are presented. (b) Illustration of relative levels of high Mw aggrecan fragments between knee healthy controls and knee injured patients
found in SF-D1 samples by Western blot. A signiﬁcant increase in one group is illustrated in black, while the rest of the fragments is shown in gray. G1 strips (3 mg sGAG per lane):
region-A (G1eG3 monomer and G1-CS2, >250 kDa), region-B (G1eCS1, 150e250 kDa) and region-C (G1-KS, 100e150 kDa). ARGS strips (0.8 mg sGAG per lane): region-A (ARGS-CS1/
CS2, 280e310 kDa), region-B (ARGS-CS1, 120e160 kDa) and band-a1 (ARGS-CS2, 390 kDa). KEEE strips (2 mg sGAG per lane): region-A (G1-KEEE and IGD-KEEE, 340e370 kDa),
band-b (CS1-KEEE, 124 kDa) and band-c (GRGT-KEEE, 50 kDa). G3 strips (1.5 mg sGAG per lane): band-1 (G1-G3 monomer, > 400 kDa), band-a (GRGT-G3, 214 kDa), band-b (GLGS-
G3, 171 kDa) and band-c (AGEG-G3, 137 kDa). The Western blot for these aggrecan fragments have been described previously33.
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we compared injury group with a reference group (Table V). SF
concentrations of the ARGS-SELE fragment showed the greatest
difference between injured and control subjects, although this
fragment was not a better biomarker than total ARGS in dis-
tinguishing injured from healthy subjects. This suggests that ARGS-
ELISA26 and electrochemiluminescence methods27 measuring total
ARGS are still the best methods for screening large numbers of
samples.
The aggrecanase generated aggrecan fragment SF-pattern from
injured knees (AIþ CI) observed here resembles qualitatively the
pattern observed in OA and acute arthritis (Supplementary data
Figs. S2 and S3;16,17,33,34). Although the difference in aggrecanase
generated fragment pattern between injury and REF was marked,no clear difference was seen between patterns observed early after
injury compared to those later after injury.
The aggrecan fragments appearing in SF are proteolytic products
of larger G1 fragments (e.g., G1eCS1, G1-SELE/KEEE and G1eG3)
present in the cartilage extracellular matrix16,17,33,42. Many knee
injuries are isolated meniscus tears or combinations of meniscus
and anterior/posterior crucial ligament injures43,44, and since the
meniscus and the ligaments contain aggrecan21,45 it is plausible
that theses tissues may contribute to the overall high aggrecan
fragment concentrations in SF following injury.
Proteolytic cleavage in the IGD of cartilage aggrecan releases the
sGAG-containing C-terminal part of the molecule which mainly
diffuses out into SF15,17,42 or into media in explant systems46,47. On
the other hand, the N-terminal G1 fragments remain in the tissue or
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induces an increase in pro-inﬂammatory cytokine levels in the
damaged joint tissues, which in turn up-regulates aggrecanolytic
enzymes, resulting in increased aggrecan degradation. Although
aggrecanase activity within the CS2 region has been proposed to be
a result of aggrecan maturation16,17,32, it is interesting to note that
these cuts in CS2 were also increased as a result of injury. An
explanation for why there is an increased cut in the CS2 region after
injury could be that aggrecanase digestion in CS2 is more preferred
than cuts in the IGD as shown for bovine10 and human aggrecan
(our data e not shown), and/or that cuts in CS2 facilitate the
removal of high Mw aggrecan fragments from injured tissues.
This study has some general limitations: (1) There is a big
difference in sGAG yield in these preparations which could be
explained by heterogeneous SF samples with differences in protein
and sGAG concentrations and in viscosities. (2) Enrichment of
aggrecan fragments is necessary before analysis by SDS-PAGE and
Western blot. Here we used dissociative CsCl centrifugation
assuming that the proportion of high Mw (>100 kDa) aggrecan
fragments present in the D1 fraction reﬂects the high Mw in vivo
content of SF. (3) There might be differences in the efﬁciency of
electro-transfer of aggrecan fragments with different size and
charge, and any differences in the afﬁnity of the antibodies for
fragments of different size carrying the same epitope would affect
the detected ratio of the signals. (4) TheWestern blot quantiﬁcation
method has a higher CV compared to methods such as ELISA.
Therefore the comparisons between groups were done using
subject median values instead of means. (5) We have used human
ARGS- and bovine G3-standards (puriﬁed from cartilage) in the
quantiﬁcation studies, which make a comparison between ARGS
and G3 fragment concentrations difﬁcult. This could be overcome if
instead using human recombinant aggrecan fragments as
standards.
Our study also has some strengths. The advantage of the
Western blot quantiﬁcation method over more regular methods
such as ELISA is that it discriminates between different proteolytic
fragments carrying the same epitopes, and therefore allows a more
detailed quantitative analysis of the products of aggrecan
proteolysis.
We have shown that in patients suffering from acute knee joint
injuries, the SF concentrations of several different aggrecanase
generated fragments are markedly increased. Both aggrecanase
cuts in the IGD and cuts in the aggrecanase CS2 sites are increased.
This change in fragment patterns is present several years after the
injury. The continued change in aggrecan turnover pattern may
contribute to the frequent development of OA following joint
injuries43.
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